Loading...
MOB logo

Moberg Pharma AB (publ)OM:MOB 주식 보고서

시가총액 SEK 540.5m
주가
SEK 11.50
SEK 13
11.5% 저평가 내재 할인율
1Y46.8%
7D-7.1%
포트폴리오 가치
​
보기

Moberg Pharma AB (publ)

OM:MOB 주식 리포트

시가총액: SEK 540.5m

Moberg Pharma (MOB) 주식 개요

제약 회사인 Moberg Pharma AB(publ)는 주로 스웨덴에서 의료 제품을 개발 및 상용화하는 회사입니다. 자세히 보기

MOB 펀더멘털 분석
스노우플레이크 점수
가치 평가0/6
미래 성장5/6
과거 실적0/6
재무 건전성6/6
배당0/6

강점

수익은 매년 93.56% 증가할 것으로 예상됩니다.

위험 분석

의미 있는 수익이 없습니다(SEK14M)

의미 있는 시가총액이 없습니다(SEK541M)


MOB Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
UNCY logo
UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
View narrative
Community Contributor
US$21.53FV • 64.4% 저평가 내재 할인율
5419.8%Revenue growth p.a.
6.2k
18
0
126
3mo ago

Moberg Pharma AB (publ) 경쟁사

가격 이력 및 성과

Moberg Pharma 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가SEK 11.50
52주 최고가SEK 14.12
52주 최저가SEK 7.25
베타1.05
1개월 변동9.52%
3개월 변동21.69%
1년 변동46.78%
3년 변동-53.82%
5년 변동-79.13%
IPO 이후 변동-95.99%

최근 뉴스 및 업데이트

MOB: Dual Terbinafine Suppliers And Broader Mandate Will Support Future Re Rating Potential

Analysts now hold the fair value estimate for Moberg Pharma steady at SEK 13.0, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that the recent review has not altered their SEK-based price target framework. What's in the News Moberg Pharma plans to propose an amendment to its articles of association at the AGM scheduled for 21 May 2026.

MOB: Dual Terbinafine Sourcing Will Support Future Re Rating Potential

Analysts have reaffirmed their price target for Moberg Pharma at SEK 13.0 per share, citing unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Regulators have approved an additional supplier of terbinafine for MOB-015, Moberg Pharma's drug for nail fungus, after a process that started in April 2024 (Key Developments).

MOB: Dual Supplier Approval Will Support Future Re Rating Potential

Analysts have maintained their SEK fair value estimate for Moberg Pharma at SEK 13.0, with unchanged assumptions for the discount rate, revenue growth, profit margin and future P/E. This suggests their view on the company’s risk and earnings outlook remains essentially intact.

Recent updates

MOB: Dual Terbinafine Suppliers And Broader Mandate Will Support Future Re Rating Potential

Analysts now hold the fair value estimate for Moberg Pharma steady at SEK 13.0, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that the recent review has not altered their SEK-based price target framework. What's in the News Moberg Pharma plans to propose an amendment to its articles of association at the AGM scheduled for 21 May 2026.

MOB: Dual Terbinafine Sourcing Will Support Future Re Rating Potential

Analysts have reaffirmed their price target for Moberg Pharma at SEK 13.0 per share, citing unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Regulators have approved an additional supplier of terbinafine for MOB-015, Moberg Pharma's drug for nail fungus, after a process that started in April 2024 (Key Developments).

MOB: Dual Supplier Approval Will Support Future Re Rating Potential

Analysts have maintained their SEK fair value estimate for Moberg Pharma at SEK 13.0, with unchanged assumptions for the discount rate, revenue growth, profit margin and future P/E. This suggests their view on the company’s risk and earnings outlook remains essentially intact.

MOB: Stable Assumptions And Profitability Outlook Will Support Future Re Rating

Analysts have maintained their SEK 13.0 price target for Moberg Pharma, reflecting unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Valuation Changes Fair Value: SEK 13.0 is unchanged, with only rounding differences between the previous SEK 13 and the current SEK 13.0 figure.

MOB: Higher Profitability Assumptions Will Support Re Rating Of Undervalued Shares

Analysts have adjusted their price target on Moberg Pharma to SEK 13.0. This reflects updated views on revenue growth, profit margin and a lower future P/E assumption. Valuation Changes Fair Value: SEK 13.0 is unchanged, indicating no revision to the overall price estimate.

MOB: Undervalued Shares Will Rely On Stable Assumptions To Re-Rate

Analysts have kept their price target for Moberg Pharma steady at SEK 13.00. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.

MOB: Europe Licensing Agreement Will Support Future Share Price Upside

Analysts have kept their price target for Moberg Pharma steady at SEK 13.0. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E despite the latest review of their model inputs. What's in the News Karo Healthcare AB and Moberg Pharma AB have signed an exclusive licensing agreement for the commercialisation of MOB-015 in 19 European markets, covering a population of about 500 million people (Key Developments).

MOB: Europe Licensing Agreement Will Support Strong Future Share Price Upside

Analysts have maintained their price target on Moberg Pharma at SEK 13.0, with unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This indicates their core view on the stock remains intact for now.

MOB: Exclusive European Licensing Deal Will Drive Strong Future Share Upside

Analysts have marginally adjusted their price target on Moberg Pharma, reiterating a fair value of SEK 13.0 per share as they maintain their assumptions for discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News Karo Healthcare AB signs an exclusive licensing agreement with Moberg Pharma for the commercialisation of MOB-015 across 19 European markets, including all major EU countries and the United Kingdom, ensuring a coordinated launch under the Lamisil brand (Company announcement) The licensing deal grants Karo responsibility for marketing, distribution, and sales in 11 countries where MOB-015 is already approved but not yet launched, accelerating the product’s European rollout (Company announcement) MOB-015, a new topical terbinafine formulation, demonstrates mycological cure rates of 76 percent in registration studies, delivering efficacy on par with oral treatment and addressing historical challenges in penetrating the nail (Company announcement) The agreement provides Moberg Pharma with access to a total addressable population of about 500 million people in Europe, significantly expanding the commercial potential of MOB-015 (Company announcement) Valuation Changes Fair Value: Unchanged at SEK 13.0 per share, reflecting a stable outlook for Moberg Pharma’s intrinsic valuation.

MOB: Exclusive Licensing Deal Will Unlock Major European Market Launches

Analysts have maintained their price target for Moberg Pharma at SEK 13.00. This reflects continued confidence in the company's earnings outlook and growth potential.

MOB: Licensing Agreement Will Drive Expansion Across Europe This Year

Analysts have raised their price target for Moberg Pharma from SEK 11 to SEK 13. This change reflects updated forecasts that consider notable shifts in anticipated revenue growth, profitability, and market conditions.

We're Not Worried About Moberg Pharma's (STO:MOB) Cash Burn

Nov 07
We're Not Worried About Moberg Pharma's (STO:MOB) Cash Burn

Shareholders Will Probably Hold Off On Increasing Moberg Pharma AB (publ)'s (STO:MOB) CEO Compensation For The Time Being

May 16
Shareholders Will Probably Hold Off On Increasing Moberg Pharma AB (publ)'s (STO:MOB) CEO Compensation For The Time Being
User avatar

Norway Expansion And EU Approvals Will Strengthen Future Position

Expansion in Norway and obtaining EU approvals bolster revenue potential and support Moberg Pharma's European growth strategy.

Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth

Feb 12
Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Sep 14
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08
Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Nov 16
Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Jan 17
Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

Dec 03
Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

주주 수익률

MOBSE PharmaceuticalsSE 시장
7D-7.1%-1.6%-1.9%
1Y46.8%-18.6%11.0%

수익률 대 산업: MOB은 지난 1년 동안 -18.6%의 수익을 기록한 Swedish Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: MOB은 지난 1년 동안 11%를 기록한 Swedish 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is MOB's price volatile compared to industry and market?
MOB volatility
MOB Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement8.1%
Market Average Movement6.6%
10% most volatile stocks in SE Market13.0%
10% least volatile stocks in SE Market3.8%

안정적인 주가: MOB는 지난 3개월 동안 Swedish 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: MOB의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.

회사 소개

설립직원 수CEO웹사이트
20066Anna Ljungwww.mobergpharma.se

제약 회사인 Moberg Pharma AB(publ)는 주로 스웨덴에서 의료 제품을 개발 및 상용화하는 회사입니다. 이 회사는 Terclara 브랜드로 손발톱 무좀 치료제 MOB-015를 제공합니다. 이 회사는 이전에는 Moberg Derma AB(publ)로 알려졌으며 2013년 5월에 Moberg Pharma AB(publ)로 사명을 변경했습니다.

Moberg Pharma AB (publ) 기초 지표 요약

Moberg Pharma의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
MOB 기초 통계
시가총액SEK 540.51m
순이익 (TTM)-SEK 27.24m
매출 (TTM)SEK 13.54m
39.9x
주가매출비율(P/S)
-19.8x
주가수익비율(P/E)

MOB는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
MOB 손익계산서 (TTM)
매출SEK 13.54m
매출원가SEK 5.86m
총이익SEK 7.68m
기타 비용SEK 34.92m
순이익-SEK 27.24m

최근 보고된 실적

Dec 31, 2025

다음 실적 발표일

May 12, 2026

주당순이익(EPS)-0.58
총이익률56.73%
순이익률-201.18%
부채/자본 비율0%

MOB의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/02 17:05
종가2026/04/30 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Moberg Pharma AB (publ)는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Bjorn RydellABG Sundal Collier Sponsored
Klas PykNordea Markets
Mats HyttingeRedeye